development phase,NME**,Biologic,Non-NME
Phase I to phase II,61%,66%,70%
Phase II to phase III,26%,34%,48%
Phase III to NDA/BLA*,49%,57%,74%
NDA/BLA to approval*,78%,88%,90%
Phase I to approval,6.2%,11.5%,22.6%
